Literature DB >> 33447241

Bone Health in Premenopausal Chinese Patients after Adjuvant Chemotherapy for Early Breast Cancer.

Claudia H W Yip1, Giok S Liem1, Frankie K F Mo1,2, Elizabeth Pang1,2, Yuan-Yuan Lei1, Leung Li1, Christopher C H Yip1, Jane Koh1,2, Rita Y W Ng1, Joyce J S Suen1, Winnie Yeo1,2.   

Abstract

BACKGROUND: In this cohort study, the objectives were to determine bone mineral density (BMD) and potential associated factors for bone health among young premenopausal patients after adjuvant chemotherapy.
METHODS: Eligibility criteria included premenopausal Chinese aged <45 years who had received adjuvant chemotherapy. At study entry, background demographics and menstrual history were collected; BMD was measured. Factors associated with reduced BMD and fracture risk were analyzed.
RESULTS: A total of 271 patients entered the study. The median time from breast cancer diagnosis to study entry was 5.0 years. The median ages at breast cancer diagnosis and at study entry were 41 and 47 years, respectively. The median BMDs for femoral neck (FN) and lumbar spine (LS) were 0.72 and 0.91 g/cm2, respectively; 40.2% had abnormal Z-scores (defined as ≤-1) and 50.2% had osteopenia/osteoporosis of either FN or LS. On multivariate analyses, factors that were identified to have a positive association with bone health (higher BMD) included higher family income (OR [95% CI] for LS = 1.573 [1.091-2.268]), taller stature (OR for LS = 2.975 [1.723-5.137]), and higher BMI (OR for FN = 2.156 [1.599-2.907]), while negatively associated factors included longer interval since last adjuvant treatment (OR for LS: 0.435 [0.250-0.757]), peri-/postmenopausal status at study entry (OR for LS = 0.443 [0.255-0.768]; OR for FN = 0.353 [0.205-0.609]), and having received adjuvant tamoxifen (OR for FN = 0.452 [0.243-0.841]).
CONCLUSION: About 5 years after breast cancer diagnosis and adjuvant chemotherapy, >50% of premenopausal patients who had received adjuvant chemotherapy were detected to have osteopenia/osteoporosis and 40% had abnormal Z-scores for FN/LS.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Cytotoxic treatment; Osteopenia; Osteoporosis

Year:  2020        PMID: 33447241      PMCID: PMC7768161          DOI: 10.1159/000506465

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  27 in total

1.  Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.

Authors:  Leena Vehmanen; Tiina Saarto; Juha Risteli; Leila Risteli; Carl Blomqvist; Inkeri Elomaa
Journal:  Breast Cancer Res Treat       Date:  2004-09       Impact factor: 4.872

2.  Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference.

Authors:  Sanford Baim; Neil Binkley; John P Bilezikian; David L Kendler; Didier B Hans; E Michael Lewiecki; Stuart Silverman
Journal:  J Clin Densitom       Date:  2008 Jan-Mar       Impact factor: 2.617

3.  Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.

Authors:  Dawn L Hershman; Donald J McMahon; Katherine D Crew; Theresa Shao; Serge Cremers; Lois Brafman; Danielle Awad; Elizabeth Shane
Journal:  J Clin Endocrinol Metab       Date:  2009-12-18       Impact factor: 5.958

4.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.

Authors:  C L Shapiro; J Manola; M Leboff
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

5.  Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

Authors:  C L Shapiro; S Halabi; V Hars; L Archer; D Weckstein; J Kirshner; W Sikov; E Winer; H J Burstein; C Hudis; C Isaacs; R Schilsky; E Paskett
Journal:  Eur J Cancer       Date:  2011-02-14       Impact factor: 9.162

6.  Risk factors and natural history of breast cancer in younger Chinese women.

Authors:  Winnie Yeo; Hang-Mei Lee; Amy Chan; Emily Yy Chan; Miranda Cm Chan; Keeng-Wai Chan; Sharon Ww Chan; Foon-Yiu Cheung; Polly Sy Cheung; Peter Hk Choi; Josette Sy Chor; William Wl Foo; Wing-Hong Kwan; Stephen Ck Law; Lawrence Pk Li; Janice Wh Tsang; Yuk Tung; Lorna Ls Wong; Ting-Ting Wong; Chun-Chung Yau; Tsz-Kok Yau; Benny Cy Zee
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.

Authors:  Dawn L Hershman; Donald J McMahon; Katherine D Crew; Serge Cremers; Dinaz Irani; Gina Cucchiara; Lois Brafman; Elizabeth Shane
Journal:  J Clin Oncol       Date:  2008-08-18       Impact factor: 44.544

8.  Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.

Authors:  P F Bruning; M J Pit; M de Jong-Bakker; A van den Ende; A Hart; A van Enk
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

9.  Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles.

Authors:  Giok S Liem; Frankie K F Mo; Elizabeth Pang; Joyce J S Suen; Nelson L S Tang; Kun M Lee; Claudia H W Yip; Wing H Tam; Rita Ng; Jane Koh; Christopher C H Yip; Grace W S Kong; Winnie Yeo
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

10.  Cancer incidence and mortality in China in 2013: an analysis based on urbanization level.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Hongmei Zeng; Tingting Zuo; Changfa Xia; Zhixun Yang; Jie He
Journal:  Chin J Cancer Res       Date:  2017-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.